Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Immune thrombocytopenia
antibodies
aplastic anemia
eltrombopag
megakaryocytes
thrombocytopenia
Journal
Cardiovascular & hematological agents in medicinal chemistry
ISSN: 1875-6182
Titre abrégé: Cardiovasc Hematol Agents Med Chem
Pays: Netherlands
ID NLM: 101266881
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2020
revised:
27
07
2020
accepted:
07
09
2020
pubmed:
12
9
2020
medline:
24
6
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Immune thrombocytopenia is an immune condition where antibodies are produced against platelets. Eltrombopag is a thrombopoietin receptor agonist that stimulates and promotes platelet production approved for treating thrombocytopenia in patients with chronic immune thrombocytopenia, where other treatments such as corticosteroids, splenectomy or immunoglobulins are inadequate. The aim of this meta-analysis was to evaluate the efficacy and safety of the eltrombopag in adults and children with immune thrombocytopenia. We included 7 studies with a total of 765 patients (606 adults and 159 children). We evaluated the number of patients that achieved a post-treatment platelet count equal or above 50x10
Identifiants
pubmed: 32914722
pii: CHAMC-EPUB-109874
doi: 10.2174/1871525718666200910161540
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
Receptors, Thrombopoietin
0
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-92Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.